Richard T Robb

US Patent:

20200376101, Dec 3, 2020

Filed:

May 22, 2020

Appl. No.:

16/881580

Inventors:

- Lombard IL, US
Richard J. Robb - Gaithersburg MD, US

International Classification:

A61K 39/00
C12Q 1/6886

Abstract:

A therapeutic vaccine and a method of cancer treatment by inducing humoral and cellular immune responses against malignant cells is provided. The vaccine comprises a delivery system that incorporates at least one peptide whose sequence encompasses a genetic mutation associated with a malignancy (neoantigen), at least one immunostimulant, and at least one type of lipid molecule.

US Patent:

20200054726, Feb 20, 2020

Filed:

Oct 9, 2019

Appl. No.:

16/597582

Inventors:

- Lombard IL, US
Richard J. Robb - Gaithersburg MD, US

International Classification:

A61K 39/00
A61K 9/00
A61K 45/06
A61K 9/127

Abstract:

A cancer therapy composition and a method of cancer treatment by inducing humoral and cellular immune responses against cancer cells in a patient is provided. The method includes administering to the patient a therapeutically effective amount of a vaccine, wherein the vaccine includes at least one tumor-associated antigen, at least one immunostimulant, and at least one lipid capable of forming a multilamellar liposome, or non-lipid molecule capable of forming a vesicle or gel. A therapeutically effective amount of at least one cell-based immunotherapeutic agent is also administered to the patient before, after, or at the same time the vaccine is administered to the patient.

US Patent:

20170224796, Aug 10, 2017

Filed:

Feb 3, 2017

Appl. No.:

15/424473

Inventors:

- Lombard IL, US
Richard J. Robb - Gaithersburg MD, US

International Classification:

A61K 39/00
C12Q 1/68

Abstract:

A therapeutic vaccine and a method of cancer treatment by inducing humoral and cellular immune responses against malignant cells is provided. The vaccine comprises a delivery system that incorporates at least one peptide whose sequence encompasses a genetic mutation associated with a malignancy (neoantigen), at least one immunostimulant, and at least one type of lipid molecule.

US Patent:

20170224797, Aug 10, 2017

Filed:

Feb 9, 2017

Appl. No.:

15/428871

Inventors:

- Lombard IL, US
Richard J. Robb - Gaithersburg MD, US

International Classification:

A61K 39/00
A61K 45/06
A61K 9/00

Abstract:

A cancer therapy composition and a method of cancer treatment by inducing humoral and cellular immune responses against cancer cells in a patient is provided. The method includes administering to the patient a therapeutically effective amount of a vaccine, wherein the vaccine includes at least one tumor-associated antigen, at least one immunostimulant, and at least one lipid capable of forming a multilamellar liposome, or non-lipid molecule capable of forming a vesicle or gel. A therapeutically effective amount of at least one cell-based immunotherapeutic agent is also administered to the patient before, after, or at the same time the vaccine is administered to the patient.